Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 30 citing articles:

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Jerry R. Mendell, Francesco Muntoni, Craig M. McDonald, et al.
Nature Medicine (2024)
Open Access | Times Cited: 20
Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
Jerry R. Mendell, Perry B. Shieh, Craig M. McDonald, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 43
Evolving regulatory perspectives on digital health technologies for medicinal product development
Seya Colloud, Thomas Metcalfe, Scott Askin, et al.
npj Digital Medicine (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 40
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)
Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald, et al.
Annals of Neurology (2023) Vol. 94, Iss. 5, pp. 955-968
Open Access | Times Cited: 38
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
Neurology (2023) Vol. 100, Iss. 15
Open Access | Times Cited: 24
Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy
Michael Rabbia, Maitea Guridi Ormazabal, Hannah Staunton, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 3, pp. 701-714
Open Access | Times Cited: 9
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
Galina Filonova, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 2, pp. 133-143
Open Access | Times Cited: 17
Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy
Alberto A. Zambon, Vandana Ayyar Gupta, Deborah Ridout, et al.
Developmental Medicine & Child Neurology (2022) Vol. 64, Iss. 8, pp. 979-988
Open Access | Times Cited: 28
Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
Neuromuscular Disorders (2022) Vol. 32, Iss. 4, pp. 271-283
Open Access | Times Cited: 23
Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
Nermina Ferizović, Jessica J. Summers, Igor Beitia Ortiz de Zárate, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0265879-e0265879
Open Access | Times Cited: 23
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304984-e0304984
Open Access | Times Cited: 5
The Relationship Between Body Mass Index and Gait Characteristics and Gait Performance of Children With Duchenne Muscular Dystrophy
Güllü Aydın Yağcıoğlu, Numan Bulut, İpek Alemdaroğlu-Gürbüz, et al.
Journal of Basic and Clinical Health Sciences (2025) Vol. 9, Iss. 1, pp. 85-91
Open Access
Effects of motor imagery adding to physiotherapy and rehabilitation program in children with Duchenne Muscular Dystrophy: does it make a difference?
Gülsena Utku Umut, Arzu Razak Özdinçler, Fitnat Ulug, et al.
European Journal of Paediatric Neurology (2025)
Closed Access
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Theodora Markati, Liesbeth De Waele, Urlike Schara-Schmidt, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 23
Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records
Joel Iff, Yi Zhong, Deepshekhar Gupta, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2906-2919
Closed Access | Times Cited: 15
The Relationship between Obesity and Clinical Outcomes in Young People with Duchenne Muscular Dystrophy
Natassja Billich, Justine Adams, Kate Carroll, et al.
Nutrients (2022) Vol. 14, Iss. 16, pp. 3304-3304
Open Access | Times Cited: 15
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease
Craig M. McDonald, Eric Camino, Rafael Escandon, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 499-523
Open Access | Times Cited: 3
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy
Anne-Fleur Schneider, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 3, pp. 343-359
Open Access | Times Cited: 21
Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial
Francesco Muntoni, Michela Guglieri, Jean K. Mah, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0272858-e0272858
Open Access | Times Cited: 10
Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine ratio , and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy
Nienke M. van de Velde, Zaïda Koeks, Mirko Signorelli, et al.
Neurology (2022) Vol. 100, Iss. 9
Open Access | Times Cited: 10
On the relevance of prognostic information for clinical trials: A theoretical quantification
Sandra Siegfried, Stephen Senn, Torsten Hothorn
Biometrical Journal (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 7
Exploring caregivers' attitudes and beliefs about nutrition and weight management for young people with Duchenne muscular dystrophy
Natassja Billich, Paula Bray, Helen Truby, et al.
Muscle & Nerve (2024) Vol. 69, Iss. 4, pp. 448-458
Open Access | Times Cited: 1
Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint
Laurent Servais, Paul Strijbos, Margaux Poleur, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy – What have we learned? 9–11 December 2022, Hoofddorp, The Netherlands
Karin J. Naarding, Georgia Stimpson, Susan J. Ward, et al.
Neuromuscular Disorders (2023) Vol. 33, Iss. 11, pp. 897-910
Closed Access | Times Cited: 3
Astaxanthin Ameliorates Worsened Muscle Dysfunction of MDX Mice Fed with a High-Fat Diet through Reducing Lipotoxicity and Regulating Gut Microbiota
Ying Chen, Chen-Jie Ling, Mengting Chen, et al.
Nutrients (2023) Vol. 16, Iss. 1, pp. 33-33
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top